Anal, Rectal (e.g., Suppositories, Etc.) Patents (Class 424/436)
  • Patent number: 11236329
    Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: February 1, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Hong M. Moulton, Ryszard Kole
  • Patent number: 10676440
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 9, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • Patent number: 10653623
    Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 19, 2020
    Assignee: Cristcot LLC
    Inventors: Jennifer J. Davagian, Raj Devarajan
  • Patent number: 10590085
    Abstract: Disclosed are compounds having the formula (I): wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: March 17, 2020
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Patent number: 10300202
    Abstract: A medicament container carrier comprising a proximal section having a first diameter, a distal section having a second diameter less than the first diameter, and at least one resilient beam arranged in the proximal section and having a beam head protruding radially to form a third diameter. The at least one beam has a non-deflected position in which the third diameter is less than the first diameter and a deflected position in which the third diameter is substantially equal to the first diameter.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: May 28, 2019
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Uwe Dasbach, Thomas Kemp
  • Patent number: 10272108
    Abstract: An antimicrobial therapeutic hydrogel composition comprises a pharmaceutical and/or medical grade silver salt, and an Aloe vera gel or extract. The composition could also include stabilizing agents, a non-ionic surfactant, polyol, and hydrophilic hygroscopic polymers. The resulting product has potent antimicrobial activity against bacteria, protozoa, fungi and viruses. The antimicrobial therapeutic composition can serve as a treatment for burns and as a wound/lesion dressing that either donates or receives moisture to provide a physiologic environment for accelerated wound healing and the relief of pain.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 30, 2019
    Inventors: Kenneth M Yates, Celia A Proctor, Dan H Atchley
  • Patent number: 9980918
    Abstract: The present disclosure relates to acid resistant banding solutions for two piece hard capsules endowed with acid resistant properties, and methods of making and using acid resistant banding solutions. The present disclosure also relates, in part, to methods for banding such acid resistant capsules which provides an acid resistant seal between the capsule parts and achieves increased acid resistance in vitro.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 29, 2018
    Assignee: Capsugel Belgium NV
    Inventors: Xiongwei He, Dominique Nicolas Cade
  • Patent number: 9849114
    Abstract: Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: December 26, 2017
    Assignee: RDD Pharma Ltd.
    Inventors: Nir Barak, Howard Lawrence Rice
  • Patent number: 9839607
    Abstract: The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5 to 5.5. A process for preparing said composition is also claimed.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 12, 2017
    Inventors: Péter Hajnal, Péter Szegó, István Nándor Antal, Judit Dredán, Imre Klebovich, Miléna Bea Lengyel
  • Patent number: 9630941
    Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: April 25, 2017
    Assignee: The University of Mississippi
    Inventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar, Mohammad Khalid Ashfaq
  • Patent number: 9402811
    Abstract: The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: August 2, 2016
    Assignee: INNOTESTO BVBA
    Inventor: Franciscus Wilhelmus Henricus Maria Merkus
  • Patent number: 9387126
    Abstract: An apparatus for cleansing wounds in which irrigant fluid from a reservoir connected to a conformable wound dressing and wound exudate from the dressing are recirculated by a device for moving fluid through a flow path which passes through the dressing and a means for fluid cleansing and back to the dressing. The cleansing means (which may be a single-phase, e.g. microfiltration, system or a two-phase, e.g. dialytic system) removes materials deleterious to wound healing, and the cleansed fluid, still containing mate rials that are beneficial in promoting wound healing, is returned to the wound bed. The dressing and a method of treatment using the apparatus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: July 12, 2016
    Assignee: Smith & Nephew PLC
    Inventors: Patrick Lewis Blott, Edward Yerbury Hartwell, Julian Lee-Webb, Derek Nicolini
  • Patent number: 9339580
    Abstract: A tampon applicator that is water-sensitive (e.g., water-soluble, water-dispersible, etc.) in that it loses its integrity over time in the presence of water is provided. The tampon applicator can be discreetly disposed of in a toilet without the risk of clogging sewer pipes. The tampon applicator includes a molded thermoplastic composition containing a cellulose derivative, a synthetic water-soluble polymer, and a plasticizer. The desired water-sensitive characteristics of the tampon applicator may be achieved in the present invention by selectively controlling a variety of aspects of the thermoplastic composition from which the applicator is formed, such as the nature of the components employed, the relative amount of each component, the manner in which the composition is formed, and so forth.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 17, 2016
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: James H. Wang, Gregory J. Wideman, Mark M. Mleziva
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Patent number: 8999360
    Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: April 7, 2015
    Inventors: Thomas Julius Borody, Soledad Carsula
  • Patent number: 8952057
    Abstract: Compositions containing polymetal complexes are useful in treating anorectal disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: JR Chem, LLC
    Inventor: José E. Ramirez
  • Patent number: 8900630
    Abstract: Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for making the microcapsules.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: December 2, 2014
    Assignee: DSM Nutritional Products
    Inventors: Nianxi Yan, Yulai Jin
  • Patent number: 8790686
    Abstract: A hemorrhoid-treating composition comprising gentian violet and a lubricant or suppository base. A method of treating hemorrhoids by topically applying a composition comprising gentian violet and a lubricant or suppository base.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: July 29, 2014
    Inventor: L. Gaye Carroll
  • Patent number: 8784900
    Abstract: Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: July 22, 2014
    Assignee: Oculus Innovative Sciences, Inc.
    Inventor: Robert Northey
  • Patent number: 8734826
    Abstract: A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: May 27, 2014
    Assignee: RDD Pharma, Ltd.
    Inventor: Nir Barak
  • Patent number: 8728511
    Abstract: Controlled release melatonin formulations are useful for imparting avoidance of mood depression which may be associated with administration of melatonin in conventional form comprising. Particular embodiments of methods use formulations designed to release melatonin according to a profile that simulates a normal endogenous melatonin nocturnal profile. The methods also include co-administration with additional medicaments.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: May 20, 2014
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Nava Zisapel, Moshe Laudon
  • Patent number: 8722013
    Abstract: The present invention relates to the use of R(+)-alpha-lipoic acid ((R)-5-(1,2-dithiolan-3-yl)valeric acid) and/or of a physiologically acceptable derivative of this compound for cryptogenic neuropathy.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: May 13, 2014
    Assignee: Encrypta GmbH
    Inventor: Klaus Wessel
  • Patent number: 8715706
    Abstract: A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active pharmaceutical ingredient as a result of elastic stressing.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 6, 2014
    Assignee: RDD Pharma, Ltd.
    Inventor: Nir Barak
  • Patent number: 8691245
    Abstract: The present invention relates to a method for forming a temporary obstruction of the intestine of a mammal, using a solidifiable composition, said composition being flowable and solidifiable to form a solid plug at a desired site within the intestine, the structure of said plug being changeable in order to allow for the subsequent, at least partial removal of the obstruction.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: April 8, 2014
    Inventor: Georg Bischof
  • Patent number: 8568292
    Abstract: A device for treating fecal incontinence in a subject is provided. The device includes a plug configured for positioning mostly within an anal canal of the subject.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: October 29, 2013
    Assignee: Renew Medical, Inc.
    Inventors: Tidhar Shalon, Guy Kotlizky
  • Patent number: 8465759
    Abstract: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: June 18, 2013
    Assignee: Auxilium US Holdings, LLC
    Inventors: Michael M. Crowley, Justin M. Keen, John J. Koleng, Feng Zhang
  • Publication number: 20130136784
    Abstract: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora.
    Type: Application
    Filed: January 23, 2013
    Publication date: May 30, 2013
    Inventor: Robert J. Staab
  • Patent number: 8449914
    Abstract: A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(?) carvedilol for obtaining the desired therapeutic effect.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: May 28, 2013
    Assignee: Egalet Ltd.
    Inventors: Christine Andersen, Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
  • Patent number: 8389535
    Abstract: Provided herein are methods of treating neuropsychiatric disorders or improving the symptoms associated therewith administering a medical food, such as L-methylfolate, to a subject having the disorder. The neuropsychiatric disorder may be an autism spectrum disorder or attention deficit disorder with or without hyperactivity (ADD/ADHD). The L-methylfolate may be administered as an adjunct to other therapeutic agents effective to treat the disorder. The subject preferably may be a child and also may have a single nucleotide polymorphism in the MTHFR gene associated with reduced expression of MTHFR enzyme. Also provided is a method of increasing the de novo synthesis of neurotransmitters in vivo by transporting a methyl-donating compound across the blood-brain barrier in a subject.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: March 5, 2013
    Inventor: Robert L. Quillin
  • Patent number: 8372425
    Abstract: The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: February 12, 2013
    Assignee: Lipid Pharmaceuticals EHF.
    Inventors: Thorsteinn Loftsson, Einar Stefansson
  • Patent number: 8206688
    Abstract: The present invention relates to a novel foam-forming composition suitable for rectal administration of locally-acting pharmaceutically active ingredients, and the product adapted to administer said foam-forming composition. Also, the present invention relates to a method for its preparation. According to the present invention a foam-forming composition is provided which exhibits a high expansion ratio and at the same time conferring optimal appearance of the formed foam to allow sufficient contact time of the active to the target site in the intestine in order to obtain optimal local effect. The composition according to the present inventions provides superior properties for the treatment of rectal diseases.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: June 26, 2012
    Assignee: Disphar International B.V.
    Inventors: Francois Jean-Louis Jerome Boutignon, Jean-Marc Aiache, Thomas Jean Henri Barres, Florian Tapissier
  • Publication number: 20110305744
    Abstract: A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da.
    Type: Application
    Filed: September 8, 2010
    Publication date: December 15, 2011
    Applicant: FARMA-DERMA SRL
    Inventor: Vincenzo Russo
  • Publication number: 20110008410
    Abstract: The invention relates to a pharmaceutical composition in the form of rectal capsules, comprising a combination, effective against malaria parasites, of artemisinine or a derivative of artemisinine, particularly artesunate, with piperaquine or a pharmaceutically acceptable salt thereof, particularly piperaquine tetraphosphate, and having high activity against Plasmodium such as, for example, Plasmodium falciparum.
    Type: Application
    Filed: December 3, 2008
    Publication date: January 13, 2011
    Inventor: Joachim Heizmann
  • Patent number: 7815929
    Abstract: A container suitable for the preparation, storage and dispensing of compounded suppositories is provided. Methods of preparing, storing and dispensing compounded suppositories utilizing such a container and related kits are also provided.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: October 19, 2010
    Assignee: CutisPharma, Inc.
    Inventors: Indu Muni, Gita Muni, Dilip Patel, Peter Mione, Denis Morin
  • Patent number: 7803574
    Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, a method of administering a composition to a patient is disclosed which comprises providing a composition-eluting device, said composition-eluting device comprising at least a first surface and a plurality of nanostructures attached to the first surface, and introducing the composition-eluting device into the body of the patient.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: September 28, 2010
    Assignee: Nanosys, Inc.
    Inventors: Tejal Desai, R. Hugh Daniels, Vijendra Sahi
  • Patent number: 7754205
    Abstract: The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 13, 2010
    Assignee: Kaneka Corporation
    Inventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
  • Publication number: 20090304776
    Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.
    Type: Application
    Filed: December 19, 2008
    Publication date: December 10, 2009
    Inventors: Totada Shantha, Jessica Shantha, Erica Shantha, Lauren Shantha
  • Patent number: 7629002
    Abstract: A polymeric antimicrobial comprising a derivative of poly(2-propenal, 2-propenoic acid) formed by reaction between a poly(2-propenal, 2-propenoic acid) and an alcohol or phenol to form protected carbonyl groups. The invention also relates to antiseptic compositions and compositions for treating gastrointestinal disease containing the polymeric antimicrobial.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: December 8, 2009
    Assignee: Chemeq Ltd.
    Inventors: Graham John Hamilton Melrose, Andrew James Huxham
  • Publication number: 20090291118
    Abstract: The Human Immunodeficiency Virus poses a significant threat to the world's population. Current strategies to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by utilizing glycoprotein 120 probes to engage a CD4 cell-surface receptor located on the surface of a T-Helper cell. Developing devices to offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. A device in the form of a solution containing a filter medium comprised of sheets or strips or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed to its surface cell-surface receptors intended to engage and neutralize the infectious nature of HIV virions provides an effective strategy to avert AIDS.
    Type: Application
    Filed: May 25, 2008
    Publication date: November 26, 2009
    Inventors: Lane Bernard Scheiber, Lane Bernard Scheiber, II
  • Publication number: 20090226495
    Abstract: The present invention is directed to attaching drugs and other functional groups to surfaces of nano-sized diamonds (NDs) to enhance the efficacy of drugs and other substances. The method involved enhancing the efficacy of a drug having an active site by acquiring a plurality of nanodiamond (ND) particles having a plurality of carbon chain surface molecules on its surface. Intermediate amine entities are covalently attached to the surface molecules of the ND particles. These are then replaces with said drug molecules such that the active sites of said drug molecules point away from the ND particle exposing them for enhanced activity and enhanced drug efficacy. The efficacy of antimicrobial drugs are enhanced, however, this may be used with many different types of drugs.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Inventors: Salvatore Charles PICARDI, Ali Razavi
  • Publication number: 20090041829
    Abstract: A tablet for oral administration comprises a lipid phase, comprised to 80% by weight or more by a mixture of (a) triglyceride, (b) mono- or/and diglyceride, and (c) cell membrane lipid; (d) one or more pharmacologically active agents dissolved or dispersed in the lipid phase; (e) water and/or ethanol; and (f) an absorption controlling amount of particulate pharmaceutical excipient. Also disclosed are granules, a suppository for rectal administration, and a capsule filled with the granules. Methods for preparing the tablet, the suppository and the granules are also disclosed as well as uses of the granules and a method for coating them.
    Type: Application
    Filed: April 27, 2006
    Publication date: February 12, 2009
    Applicant: Galenica Technology AB
    Inventors: Bengt Herslof, Henri Hansson, Per Tingvall
  • Publication number: 20090035354
    Abstract: A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter.
    Type: Application
    Filed: December 14, 2006
    Publication date: February 5, 2009
    Inventor: Nir Barak
  • Publication number: 20080274162
    Abstract: This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus Lactobacillus. More specifically, the invention relates to the utilization of one or more species or strains of Lactobacillus producing bacteria for the control of urinary tract bacteria and pathogens, including antibiotic-resistant urinary tract pathogens, and their associated diseases by both a reduction in the rate of colonization of the infection and pathogens.
    Type: Application
    Filed: May 4, 2007
    Publication date: November 6, 2008
    Inventors: Jeffrey Bryan Nessa, Beth Ann Nessa
  • Publication number: 20080241216
    Abstract: A preparation containing active and/or auxiliary substance(s) for the time- and/or dose-controllable release of said substances, comprising at least two layers (1, 2) in rolled or folded shape, is characterized in that a) the first layer contains at least one active or auxiliary substance, is continuous at least in sections thereof, that at least one of the parameters thickness, width and concentration of the active and/or auxiliary substance of this layer is not constant, and b) in that the second layer is continuous and possesses a lower moisture permeability than the first layer.
    Type: Application
    Filed: February 14, 2008
    Publication date: October 2, 2008
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Christian VON FALKENHAUSEN, Markus KRUMME
  • Patent number: 7427416
    Abstract: Methods of treating conditions using metal-containing materials are disclosed. Exemplary conditions include bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths, cancerous conditions and combinations of such conditions. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: September 23, 2008
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, James Alexander Robert Stiles
  • Publication number: 20080213339
    Abstract: The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least one flavonoid derivative or a polypeptide or with a mixture of such compounds.
    Type: Application
    Filed: July 21, 2006
    Publication date: September 4, 2008
    Inventors: Roger Imboden, Erich Rothenbuhler, Juerg Lutz
  • Patent number: 7404965
    Abstract: A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of alprazolam to a subject, which includes as a permeation enhancing mixture a fatty component in an amount of 0.1% to 20% by weight which is one of (a) a saturated fatty alcohol of formula CH3—(CH2)n—CH2OH, a saturated fatty acid of formula CH3—(CH2)n—CH2COOH, (b) an unsaturated fatty alcohol of formula CH3(CnH2(n?1))—OH, or (c) a fatty acid of formula CH3(CnH2(n?1))—COOH, wherein n is an integer of between 8 and 22; and a vehicle that includes a C1-C4 alkanol, a polyalcohol, and water.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: July 29, 2008
    Assignee: Antares Pharma IPL AG
    Inventors: Dario Carrara, Gabriel Porto, Jorge Rodriguez
  • Publication number: 20080160065
    Abstract: One embodiment provides an insert, which includes a non-degradable hydrogel matrix and clindamycin hydrochloride in contact with the matrix, wherein the insert is suitable for mammalian intravaginal, buccal, or intrarectal use. Methods of using and making the insert are also provided.
    Type: Application
    Filed: July 12, 2007
    Publication date: July 3, 2008
    Inventors: Janet Anne HALLIDAY, Denis Andrew CARR, Lynn BOYD, Monica MACGREGOR, Audrey THOM, Linda KELLY, Mark Alexander LIVINGSTONE, Lilias Morton CURRIE
  • Patent number: 7381419
    Abstract: Optimum compounding composition of a local injection preparation for treating rectal submucous lesioned abnormal tissue with local anesthetic is decided to provide a medical composition kit. In a composition kit for the treatment where respective containers are unsealed upon being used and respective contents are mixed to obtain a preparation for injection, a medical composition kit which is characterized in that respective single doses of a therapeutic preparation and local anesthetic are fractionally charged in containers, the said therapeutic preparation contains 1˜10% of a water-soluble aluminum compound and 0.01˜2% of tannic acid and the said local anesthetic contains 0.1˜1% of lidocaine hydrochloride or 0.5˜5% of procaine hydrochloride.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: June 3, 2008
    Assignees: Lequio Pharma Co., Ltd., Mitsubishi Pharma Corporation
    Inventors: Kinuko Oku, Takako Iwamoto, Takashi Ono
  • Patent number: 7344732
    Abstract: A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body that is manufactured at a first manufacturing facility; and a dosage form coupled to the body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form is manufactured at a second manufacturing facility. Also, a method for producing a medicated tampon including manufacturing a tampon body at a first manufacturing facility; manufacturing a dosage form at a second manufacturing facility, wherein the dosage form includes a formulation including a therapeutic agent; and coupling the dosage form to the tampon body.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: March 18, 2008
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventor: Steven Craig Gehling